{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:15:08Z","timestamp":1789528508282,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22173020"],"award-info":[{"award-number":["22173020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22573016"],"award-info":[{"award-number":["22573016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijbiomac.2025.149073","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:13:40Z","timestamp":1763640820000},"page":"149073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P1","title":["Drug repurposing and AI-driven discovery of tyrosinase inhibitors, emerging strategies for skin disorders: A review"],"prefix":"10.1016","volume":"334","author":[{"given":"Majid","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izhar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0005","article-title":"Influences on skin and intrinsic aging: biological, environmental, and therapeutic insights","volume":"24","author":"Hussein","year":"2025","journal-title":"Cosmet. Dermatol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0010","first-page":"302","article-title":"Anatomy of the Skin: Structure and Functions of the Epidermis and Dermis","volume":"1","author":"Mirzayev","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0015","series-title":"The Skin","author":"Peate","year":"2025"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s43856-024-00550-7","article-title":"Melanometry for objective evaluation of skin pigmentation in pulse oximetry studies","volume":"4","author":"Vasudevan","year":"2024","journal-title":"Commun. Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149073_bb0025","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.3390\/molecules28124839","article-title":"Skin pigmentation types, causes and treatment-a review","volume":"28","author":"Thawabteh","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149073_bb0030","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/exd.14260","article-title":"Skin pigmentation and its control: From ultraviolet radiation to stem cells","volume":"30","author":"Yardman-Frank","year":"2021","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0035","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3390\/healthcare11142091","article-title":"Human skin pigmentation: from a biological feature to a social determinant","author":"Mosca","year":"2023","journal-title":"Healthcare"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149073_bb0040","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.3390\/ijms22073727","article-title":"Skin pigmentation abnormalities and their possible relationship with skin aging","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2025.01.001","article-title":"Unfolded protein response modulates Tyrosinase levels and melanin production during melanogenesis","volume":"117","author":"Yamazaki","year":"2025","journal-title":"J. Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jpp\/rgad107","article-title":"Dysregulation of tyrosinase activity: a potential link between skin disorders and neurodegeneration","volume":"76","author":"Jin","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512152","article-title":"Melanocortin 1 receptor (MC1R): potentials as therapeutic targets","volume":"24","author":"Mun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0060","first-page":"74","article-title":"Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome \/ toxic epidermal necrolysis","volume":"43","author":"Wu","year":"2025","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1440187","article-title":"The biochemistry of melanogenesis: an insight into the function and mechanism of melanogenesis-related proteins","volume":"11","author":"Wang","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0070","series-title":"Hair Care Products: Efficacy, Safety and Global Regulation","first-page":"23","article-title":"The genetics and molecular mechanism of hair color: from melanocyte development to pigment synthesis","author":"Tripathi","year":"2024"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1452558","article-title":"Preliminary screening of biomarkers and drug candidates in a mouse model of \u03b2-thalassemia based on quasi-targeted metabolomics","volume":"15","author":"Guo","year":"2024","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129742","article-title":"Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy","volume":"104","author":"Dai","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115574","article-title":"Targeting tyrosinase in hyperpigmentation: current status, limitations and future promises","volume":"212","author":"Zolghadri","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00360-022-01468-z","article-title":"Insect phenoloxidase and its diverse roles: melanogenesis and beyond","volume":"193","author":"Marieshwari","year":"2023","journal-title":"J. Comp. Physiol. B"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12893-021-01298-w","article-title":"Identification of potential hub genes associated with skin wound healing based on time course bioinformatic analyses","volume":"21","author":"Zhu","year":"2021","journal-title":"BMC Surg."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111892","article-title":"Tyrosinase inhibitors as potential antibacterial agents","volume":"187","author":"Yuan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149073_bb0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/08916934.2020.1836489","article-title":"Autoimmune response against tyrosinase induces depigmentation in C57BL\/6 black mice","volume":"53","author":"Al Robaee","year":"2020","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11274-021-03186-0","article-title":"Application of bacterial tyrosinases in organic synthesis","volume":"38","author":"Agunbiade","year":"2022","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0115","series-title":"Microbial Products","first-page":"25","article-title":"Microbial melanin: role, biosynthesis, and applications","author":"Kumar","year":"2022"},{"issue":"33","key":"10.1016\/j.ijbiomac.2025.149073_bb0120","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205619119","article-title":"Elucidation of the tyrosinase\/O2\/monophenol ternary intermediate that dictates the monooxygenation mechanism in melanin biosynthesis","volume":"119","author":"Kipouros","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.138293","article-title":"Enzyme-driven oxygen-fuelled pathway selectivity of tyrosine-containing peptide oxidation evolution","volume":"450","author":"Ren","year":"2022","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-021-02913-6","article-title":"Engineered tyrosinases with broadened bio-catalysis scope: immobilization using nanocarriers and applications","volume":"11","author":"Hussain","year":"2021","journal-title":"3 Biotech"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0135","series-title":"Microbial Enzymes: Production, Purification and Industrial Applications","first-page":"665","article-title":"Microbial laccases: structure, function, and applications","author":"Gupta","year":"2025"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/B978-0-12-823974-2.00003-6","article-title":"Tyrosinase enzyme and its inhibitors: an update of the literature","author":"Carradori","year":"2024","journal-title":"Metalloenzymes"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115655","article-title":"Recent advances in triazoles as tyrosinase inhibitors","volume":"259","author":"Mermer","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.149073_bb0150","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1080\/10408398.2021.1871724","article-title":"A systematic review of synthetic tyrosinase inhibitors and their structure-activity relationship","volume":"62","author":"Peng","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10529-025-03570-y","article-title":"In-silico evaluation of potential plant-based tyrosinase inhibitors for cosmetic and pharmaceutical applications","volume":"47","author":"Srivastava","year":"2025","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0160","series-title":"Drug Repurposing: Hypothesis, Molecular Aspects and Therapeutic Applications","first-page":"3","article-title":"Drug repurposing (DR): an emerging approach in drug","author":"Rudrapal","year":"2020"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: an effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0170","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv. Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149073_bb0175","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149073_bb0180","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11886-021-01484-5","article-title":"Drug repurposing: claiming the full benefit from drug development","volume":"23","author":"Kort","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0185","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.csbj.2020.04.004","article-title":"Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs","volume":"18","author":"Parisi","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149073_bb0190","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/1061186X.2024.2365934","article-title":"Harnessing machine learning potential for personalised drug design and overcoming drug resistance","volume":"32","author":"Hakami","year":"2024","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149073_bb0195","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.fmre.2024.04.021","article-title":"Role of artificial intelligence in revolutionizing drug discovery","volume":"5","author":"Rehman","year":"2024","journal-title":"Fundam. Res."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.149073_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300816","article-title":"The role of AI in drug discovery","volume":"25","author":"Abbas","year":"2024","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.149073_bb0210","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1080\/17568919.2025.2550925","article-title":"Flavonols as potent inhibitors of tyrosinase & pancreatic lipase: synthesis, docking, MD simulation, DFT, and ADMET","volume":"17","author":"Mughal","year":"2025","journal-title":"Future Med. Chem."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.149073_bb0215","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/17568919.2025.2539672","article-title":"Piperidines as dual inhibitors of tyrosinase and pancreatic lipase: in vitro and in silico mechanistic insights","volume":"17","author":"Naeem","year":"2025","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0220","series-title":"Metalloenzymes","first-page":"533","article-title":"Tyrosinase enzyme and its inhibitors: an update of the literature","author":"Carradori","year":"2024"},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.149073_bb0225","doi-asserted-by":"crossref","first-page":"17195","DOI":"10.1021\/acsomega.3c01566","article-title":"Evaluation of 2,3-dihydro-1,5-benzothiazepine derivatives as potential tyrosinase inhibitors: in vitro and in silico studies","volume":"8","author":"Al-Rooqi","year":"2023","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.149073_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112788","article-title":"Novel virtual screening approach for the discovery of human tyrosinase inhibitors","volume":"9","author":"Ai","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0235","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jid.2022.06.026","article-title":"Toward new depigmenting agents through repurposing existing drugs: substituted hydroxyquinolines as melanogenesis inhibitors","volume":"143","author":"Germanas","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605714","article-title":"Repurposing of drug candidates for treatment of skin cancer","volume":"10","author":"Cortes","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0245","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1515\/9783110791150-013","article-title":"Advantages, opportunities, and challenges to drug repurposing","author":"Sharma","year":"2023","journal-title":"Drug Repurp"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103422","article-title":"Drug repurposing using real-world data","volume":"28","author":"Tan","year":"2023","journal-title":"Drug Discov.Today"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0255","article-title":"A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery","volume":"195","author":"Thanigaimalai Pillaiyar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149073_bb0260","doi-asserted-by":"crossref","first-page":"28534","DOI":"10.3390\/ijms161226114","article-title":"Repositioning of thiourea-containing drugs as tyrosinase inhibitors","volume":"16","author":"Choi","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149073_bb0265","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s13318-021-00716-x","article-title":"Advances in thiopurine drug delivery: the current state-of-the-art","volume":"46","author":"Bayoumy","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0270","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/ijms19010077","article-title":"Thiopurine drugs repositioned as tyrosinase inhibitors","volume":"19","author":"Choi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2015.10.033","article-title":"Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase","volume":"106","author":"Choi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0280","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijbiomac.2017.04.058","article-title":"Rifampicin as a novel tyrosinase inhibitor: Inhibitory activity and mechanism","volume":"102","author":"Chai","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149073_bb0285","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/molecules30040900","article-title":"Rifampicin repurposing reveals anti-melanogenic activity in B16F10 melanoma cells","volume":"30","author":"Lee","year":"2025","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/ph18020224","article-title":"Drug repurposing of voglibose, a diabetes medication for skin health","volume":"18","author":"Kim","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125587","article-title":"Discovery of amphotericin B, an antifungal drug as tyrosinase inhibitor with potent anti-melanogenic activity","volume":"246","author":"Mahalapbutr","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.149073_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202401035","article-title":"A repurposing pipeline to candidate-suitable inhibitors of tyrosinase: computational and bioassay studies","volume":"21","author":"Kabiri","year":"2024","journal-title":"Chem. Biodivers."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24470","article-title":"Anti-enzymatic and DNA docking studies of montelukast: a multifaceted molecular scaffold with in vitro investigations, molecular expression analysis and molecular dynamics simulations","volume":"10","author":"Abdullah","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/Pigmentinternational.Pigmentinternational_9_20","article-title":"Tranexamic acid in melasma: a review","volume":"7","author":"Kaur","year":"2020","journal-title":"Pigment. Int."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149073_bb0315","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/cosmetics9050108","article-title":"Mechanism of action of topical tranexamic acid in the treatment of melasma and sun-induced skin hyperpigmentation","volume":"9","author":"Maeda","year":"2022","journal-title":"Cosmetics"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149073_bb0320","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5021\/ad.2015.27.3.250","article-title":"Tranexamic acid diminishes laser-induced melanogenesis","volume":"27","author":"Kim","year":"2015","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0325","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2147\/CCID.S479411","article-title":"Tranexamic acid for the treatment of hyperpigmentation and telangiectatic disorders other than melasma: an update","author":"Chen","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149073_bb0330","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: a clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J. Europ. Acad. Derma."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0335","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.13424","article-title":"Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0340","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/CCID.S202285","article-title":"Evaluation of the safety and efficacy of a triple combination cream (hydroquinone, tretinoin, and fluocinolone) for treatment of melasma in Middle Eastern skin","author":"Ahmad Nasrollahi","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.149073_bb0345","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40257-024-00863-2","article-title":"An update on new and existing treatments for the management of melasma","volume":"25","author":"Gan","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.149073_bb0350","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jid.2018.01.019","article-title":"Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase","volume":"138","author":"Mann","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0355","doi-asserted-by":"crossref","first-page":"s543","DOI":"10.25251\/skin.10.supp.543","article-title":"Thiamidol (isobutylamido thiazolyl resorcinol): a highly specific human tyrosinase inhibitor for the treatment of hyperpigmentation","volume":"9","author":"Mann","year":"2025","journal-title":"Skin: J. Cutan. Med"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.149073_bb0360","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jid.2019.02.013","article-title":"Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma","volume":"139","author":"Arrowitz","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149073_bb0365","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/jvc2.378","article-title":"Hyperpigmentation in skin of colour: therapeutical benefits of isobutylamido-thiazolyl-resorcinol (Thiamidol\u00ae), an effective tyrosinase inhibitor, in phototypes IV\u2013VI","volume":"3","author":"Schuster","year":"2024","journal-title":"JEADV Clin. Pract."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40364-025-00758-2","article-title":"Integrating artificial intelligence in drug discovery and early drug development: a transformative approach","volume":"13","author":"Ocana","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0375","series-title":"Microbial Data Intelligence and Computational Techniques for Sustainable Computing","first-page":"1","article-title":"The contribution of artificial intelligence to drug discovery: current progress and prospects for the future","author":"Gupta","year":"2024"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0380","series-title":"AI-Assisted Computational Approaches for Immunological Disorders","first-page":"143","article-title":"AI-driven drug discovery, design, and development in immunological disorders","author":"Ogidi","year":"2025"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0385","article-title":"User-friendly and industry-integrated AI for medicinal chemists and pharmaceuticals","volume":"2","author":"Kapustina","year":"2024","journal-title":"Artif. Intel. Chem."},{"issue":"18","key":"10.1016\/j.ijbiomac.2025.149073_bb0390","doi-asserted-by":"crossref","first-page":"9983","DOI":"10.3390\/ijms22189983","article-title":"Comprehensive survey of recent drug discovery using deep learning","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149073_bb0395","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s10462-021-10058-4","article-title":"Machine learning in drug discovery: a review","volume":"55","author":"Dara","year":"2022","journal-title":"Artif. Intell. Rev."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0400","series-title":"Biophysical and Computational Tools in Drug Discovery","first-page":"221","article-title":"Generative AI models for drug discovery","author":"Tang","year":"2021"},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.149073_bb0405","doi-asserted-by":"crossref","first-page":"14011","DOI":"10.1021\/acs.jmedchem.1c00927","article-title":"Generative models for de novo drug design","volume":"64","author":"Tong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0410","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neucom.2021.04.039","article-title":"Molecular generative graph neural networks for drug discovery","volume":"450","author":"Bongini","year":"2021","journal-title":"Neurocomputing"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149073_bb0415","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.drudis.2021.02.011","article-title":"Graph neural networks for automated de novo drug design","volume":"26","author":"Xiong","year":"2021","journal-title":"Drug Discov.Today"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.149073_bb0420","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/17460441.2025.2490835","article-title":"Natural language processing in drug discovery: bridging the gap between text and therapeutics with artificial intelligence","volume":"20","author":"Withers","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0425","series-title":"Clinical Applications of Artificial Intelligence in Real-World Data","first-page":"69","article-title":"Natural Language processing and text mining (turning unstructured data into structured)","author":"Bagheri","year":"2023"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.149073_bb0430","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1021\/acs.jmedchem.4c00091","article-title":"Artificial intelligence-assisted optimization of antipigmentation tyrosinase inhibitors: de novo molecular generation based on a low activity lead compound","volume":"67","author":"Cai","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6\u20137","key":"10.1016\/j.ijbiomac.2025.149073_bb0435","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/minf.201100021","article-title":"A comparative study of nonlinear machine learning for the \u201cin silico\u201d depiction of tyrosinase inhibitory activity from molecular structure","volume":"30","author":"Le-Thi-Thu","year":"2011","journal-title":"Mo. Inform."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.149073_bb0440","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov.Today"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0445","first-page":"1","article-title":"The drug repurposing ecosystem: intellectual property incentives, market exclusivity, and the future of new medicines","volume":"20","author":"Halabi","year":"2018","journal-title":"Yale J. Law & Technol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149073_bb0450","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acsptsci.3c00361","article-title":"Drug repurposing: a leading strategy for new threats and targets","volume":"7","author":"Mishra","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0455","series-title":"Drug Repurposing in Dermatology: Molecular Biology and Omics Approach","author":"Badria","year":"2020"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0460","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/bs.pmbts.2024.02.005","article-title":"Drug repurposing for regenerative medicine and cosmetics: scientific, technological and economic issues","volume":"207","author":"Vu","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.149073_bb0465","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acsptsci.4c00679","article-title":"Drug repurposing and nanotechnology for topical skin cancer treatment: redirecting toward targeted and synergistic antitumor effects","volume":"8","author":"Martins","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0470","series-title":"Drug Development and Safety","author":"Rauf","year":"2024"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0475","series-title":"Repurposing and Morphing: A Combined Strategy to Design Multi Target Ligands","author":"Artasensi","year":"2022"},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2024.1377443","article-title":"Ensuring safety and efficacy in combination products: regulatory challenges and best practices","volume":"6","author":"Gupta","year":"2024","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.ijbiomac.2025.149073_bb0485","series-title":"Translational Urology","first-page":"293","article-title":"Regulatory considerations for new drugs and devices","author":"Chen","year":"2025"},{"issue":"S1","key":"10.1016\/j.ijbiomac.2025.149073_bb0490","doi-asserted-by":"crossref","first-page":"34","DOI":"10.53730\/ijhs.v4nS1.15020","article-title":"Regulatory challenges in pharmaceuticals: navigating global compliance and approval","volume":"4","author":"Alharbi","year":"2020","journal-title":"Int. J. Health Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.149073_bb0495","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov.Today"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.149073_bb0500","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The drug repurposing hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.149073_bb0505","doi-asserted-by":"crossref","DOI":"10.1002\/ffo2.210","article-title":"Horizon scanning methods for identification of new and repurposed medicines for stakeholders in the United Kingdom","volume":"7","author":"Khan","year":"2025","journal-title":"Futures Foresight Sci."},{"issue":"753","key":"10.1016\/j.ijbiomac.2025.149073_bb0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl0998","article-title":"New government drug repurposing programs: opportunities and uncertainties","volume":"16","author":"Liddicoat","year":"2024","journal-title":"Sci. Transl. Med."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025096308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025096308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:48:44Z","timestamp":1778716124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025096308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":102,"alternative-id":["S0141813025096308"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149073","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing and AI-driven discovery of tyrosinase inhibitors, emerging strategies for skin disorders: A review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.149073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149073"}}